DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Saturday morning. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $4.99 on Friday. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $8.32. The company has a 50-day moving average of $4.48 and a 200-day moving average of $3.83. The company has a market cap of $102.64 million, a P/E ratio of -1.11 and a beta of 0.71.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.